We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-6.84%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$23.1B
AUM Growth
-$3.48B
Cap. Flow
-$129M
Cap. Flow %
-0.56%
Top 10 Hldgs %
80.48%
Holding
138
New
11
Increased
23
Reduced
15
Closed
12

Top Buys

Rank Stock Value
1
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$126M
2
IMCR icon
Immunocore
IMCR
+$112M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$106M
4
TIL icon
Instil Bio
TIL
+$99.9M
5
DSGN icon
Design Therapeutics
DSGN
+$48.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$737M
2
KRRO icon
Korro Bio
KRRO
+$31.1M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$22.5M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$13M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.81%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGS icon
51
Aligos Therapeutics
ALGS
$41.7M
$36.6M 0.16%
64,400
– –
AXSM icon
52
Axsome Therapeutics
AXSM
$10.9B
$35.6M 0.15%
628,414
-150,420
-19% -$10.6M
ADCT icon
53
ADC Therapeutics
ADCT
$127M
$34.6M 0.15%
1,418,107
– –
CCXI
54
DELISTED
ChemoCentryx, Inc.
CCXI
$33.6M 0.15%
656,710
– –
OPT
55
DELISTED
Opthea Limited American Depositary Shares
OPT
$31.7M 0.14%
3,308,705
– –
SYRE icon
56
Spyre Therapeutics
SYRE
$9.39B
$27M 0.12%
136,404
– –
NVAX icon
57
Novavax
NVAX
$1.47B
$26.1M 0.11%
143,756
-25,950
-15% -$5.17M
ALKS icon
58
Alkermes
ALKS
$8.11B
$22.9M 0.1%
1,228,170
-306,979
-20% -$6.28M
MREO
59
Mereo BioPharma
MREO
$46.4M
$22.6M 0.1%
6,719,948
+689,655
+11% +$2.44M
RETA
60
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$22.3M 0.1%
223,976
– –
OTIC
61
DELISTED
Otonomy, Inc.
OTIC
$18.4M 0.08%
+7,220,074
New +$29.6M
AUPH icon
62
Aurinia Pharmaceuticals
AUPH
$2.22B
$18.3M 0.08%
1,410,064
– –
EWTX icon
63
Edgewise Therapeutics
EWTX
$4.8B
$16.3M 0.07%
+500,000
New +$16.2M
XNCR icon
64
Xencor
XNCR
$2.07B
$15.9M 0.07%
369,370
– –
LONA
65
LeonaBio Inc
LONA
$72.4M
$14.8M 0.06%
80,637
– –
ALBO
66
DELISTED
Albireo Pharma Inc
ALBO
$14.5M 0.06%
412,466
– –
XENE icon
67
Xenon Pharmaceuticals
XENE
$5.88B
$13.5M 0.06%
751,639
+64,253
+9% +$1.09M
MIRM icon
68
Mirum Pharmaceuticals
MIRM
$5.87B
$12.8M 0.06%
647,313
– –
KDNY
69
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.6M 0.05%
748,693
– –
SPRY icon
70
ARS Pharmaceuticals
SPRY
$547M
$10.4M 0.05%
238,095
– –
RVMD icon
71
Revolution Medicines
RVMD
$44.9B
$10.2M 0.04%
+222,222
New +$9.97M
CBAY
72
DELISTED
Cymabay Therapeutics
CBAY
$9.85M 0.04%
2,170,464
-722,812
-25% -$3.89M
GTH
73
DELISTED
Genetron Holdings Limited ADS
GTH
$9.77M 0.04%
151,769
– –
HOOK
74
DELISTED
HOOKIPA Pharma
HOOK
$9.42M 0.04%
70,048
– –
CRNX icon
75
Crinetics Pharmaceuticals
CRNX
$8.99B
$9.42M 0.04%
616,520
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2021 Portfolio in Review

As of Q1 2021, Julian Baker held 138 positions worth $23.1B, down 13% from $26.5B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Julian Baker's Q1 2021 filing shows 11 new, 23 increased, 15 reduced and 12 closed positions. Its largest new stake was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M. The largest sale was Alexion Pharmaceuticals, an estimated $737M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q1 2021 buy was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M.
  • Julian Baker added most to Global Blood Therapeutics, Inc. in Q1 2021, an estimated $106M increase.
  • Julian Baker's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $737M.
  • Julian Baker fully exited Adaptive Biotechnologies in Q1 2021, selling an estimated $22.5M.
  • Julian Baker's ten largest holdings make up 80% of its $23.1B portfolio in Q1 2021.
  • Julian Baker opened 11 new positions and closed 12 in Q1 2021.
  • Julian Baker's portfolio value fell 13% quarter-over-quarter to $23.1B.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.